Provexis (PXS) Stock Overview
Develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PXS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Provexis plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.011 |
| 52 Week High | UK£0.015 |
| 52 Week Low | UK£0.004 |
| Beta | 0.54 |
| 1 Month Change | -25.35% |
| 3 Month Change | 31.90% |
| 1 Year Change | 138.89% |
| 3 Year Change | 36.08% |
| 5 Year Change | 25.73% |
| Change since IPO | -83.00% |
Recent News & Updates
Recent updates
We're Not Very Worried About Provexis' (LON:PXS) Cash Burn Rate
Dec 10
We're Keeping An Eye On Provexis' (LON:PXS) Cash Burn Rate
Mar 05We're Not Very Worried About Provexis' (LON:PXS) Cash Burn Rate
Jan 21We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
Jun 30We're Not Worried About Provexis' (LON:PXS) Cash Burn
Feb 15We're Interested To See How Provexis (LON:PXS) Uses Its Cash Hoard To Grow
Oct 28Shareholder Returns
| PXS | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | -2.3% | -2.5% | 0.4% |
| 1Y | 138.9% | -13.0% | 15.0% |
Return vs Industry: PXS exceeded the UK Personal Products industry which returned -13% over the past year.
Return vs Market: PXS exceeded the UK Market which returned 15% over the past year.
Price Volatility
| PXS volatility | |
|---|---|
| PXS Average Weekly Movement | 10.8% |
| Personal Products Industry Average Movement | 5.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 3.0% |
Stable Share Price: PXS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: PXS's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2 | Ian Ford | www.provexis.com |
Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. It also provides Fruitflow+ Omega-3, a dietary supplement product.
Provexis plc Fundamentals Summary
| PXS fundamental statistics | |
|---|---|
| Market cap | UK£25.22m |
| Earnings (TTM) | -UK£603.80k |
| Revenue (TTM) | UK£871.27k |
Is PXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PXS income statement (TTM) | |
|---|---|
| Revenue | UK£871.27k |
| Cost of Revenue | UK£442.30k |
| Gross Profit | UK£428.97k |
| Other Expenses | UK£1.03m |
| Earnings | -UK£603.80k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00026 |
| Gross Margin | 49.24% |
| Net Profit Margin | -69.30% |
| Debt/Equity Ratio | 0% |
How did PXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/29 20:50 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Provexis plc is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.